The Seroprevalence of Hepatitis C Virus (HCV) in Hemodialysis Patients in Oman: A National Cross-Sectional Study.
Cross-sectional
Dialysis unit
Hepatitis C virus
Oman
Seroprevalence
Journal
Journal of epidemiology and global health
ISSN: 2210-6014
Titre abrégé: J Epidemiol Glob Health
Pays: Switzerland
ID NLM: 101592084
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
13
07
2023
accepted:
29
08
2023
medline:
30
11
2023
pubmed:
12
9
2023
entrez:
12
9
2023
Statut:
ppublish
Résumé
HCV infection in hemodialysis units is a significant cause of morbidity and mortality. The risk of HCV infection among dialysis patients is higher compared to the general population due to high potential blood exposures in hemodialysis settings. This study aims to assess the national HCV seroprevalence in selected dialysis units and to determine the risk factors for acquiring HCV infection. This cross-sectional study was conducted from 1 January to 31 March 2021. A total of 734 patients from 11 hemodialysis centers in Oman were included. Samples were tested simultaneously for HCV antibodies and HCV RNA. HCV genotyping was determined in all viremic patients. Demographic and hemodialysis center related data were gathered and their association with the positive HCV serology were explored using univariate and multivariate logistic regression analysis. Out of 800 patients selected from 11 dialysis units for the study, 734 patients (91.8%) were included. The overall seroprevalence of HCV infection among hemodialysis patients was 5.6%. (41/734). HCV RNA was detected in 31.7% (13/41) of seropositive hemodialysis patients. The most common genotype was subtype 1a, followed by subtype 3. Variables associated with high HCV prevalence were family history of HCV and duration of dialysis. The prevalence of infection within hemodialysis patients in Oman has significantly decreased but remained higher than the general population. Continuous monitoring and follow-up, including periodic serosurvey and linkage to care and treatment are recommended. Additionally, practice audits are recommended for identifying gaps and ensuring sustainability of best practices and further improvement.
Sections du résumé
BACKGROUND
BACKGROUND
HCV infection in hemodialysis units is a significant cause of morbidity and mortality. The risk of HCV infection among dialysis patients is higher compared to the general population due to high potential blood exposures in hemodialysis settings. This study aims to assess the national HCV seroprevalence in selected dialysis units and to determine the risk factors for acquiring HCV infection.
METHODS
METHODS
This cross-sectional study was conducted from 1 January to 31 March 2021. A total of 734 patients from 11 hemodialysis centers in Oman were included. Samples were tested simultaneously for HCV antibodies and HCV RNA. HCV genotyping was determined in all viremic patients. Demographic and hemodialysis center related data were gathered and their association with the positive HCV serology were explored using univariate and multivariate logistic regression analysis.
RESULTS
RESULTS
Out of 800 patients selected from 11 dialysis units for the study, 734 patients (91.8%) were included. The overall seroprevalence of HCV infection among hemodialysis patients was 5.6%. (41/734). HCV RNA was detected in 31.7% (13/41) of seropositive hemodialysis patients. The most common genotype was subtype 1a, followed by subtype 3. Variables associated with high HCV prevalence were family history of HCV and duration of dialysis.
CONCLUSION
CONCLUSIONS
The prevalence of infection within hemodialysis patients in Oman has significantly decreased but remained higher than the general population. Continuous monitoring and follow-up, including periodic serosurvey and linkage to care and treatment are recommended. Additionally, practice audits are recommended for identifying gaps and ensuring sustainability of best practices and further improvement.
Identifiants
pubmed: 37698781
doi: 10.1007/s44197-023-00149-6
pii: 10.1007/s44197-023-00149-6
pmc: PMC10686920
doi:
Substances chimiques
RNA
63231-63-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
774-781Informations de copyright
© 2023. The Author(s).
Références
Expert Rev Gastroenterol Hepatol. 2020 Jul;14(7):579-590
pubmed: 32613874
PLoS One. 2020 May 14;15(5):e0232931
pubmed: 32407423
J Hepatol. 2006 Oct;45(4):529-38
pubmed: 16879891
World J Gastroenterol. 2017 Jan 7;23(1):151-166
pubmed: 28104991
Lancet Gastroenterol Hepatol. 2022 May;7(5):426-445
pubmed: 35303490
Arch Virol. 2022 Mar;167(3):717-736
pubmed: 35089390
Saudi J Kidney Dis Transpl. 2021 Nov-Dec;32(6):1715-1721
pubmed: 35946285
Saudi J Kidney Dis Transpl. 2020 Jul-Aug;31(4):826-830
pubmed: 32801244
BMC Infect Dis. 2022 Nov 14;22(1):848
pubmed: 36376846
Kidney Int. 2004 Jun;65(6):2335-42
pubmed: 15149347
Kidney Int Suppl (2011). 2018 Oct;8(3):91-165
pubmed: 30675443
Sultan Qaboos Univ Med J. 2017 Nov;17(4):e404-e410
pubmed: 29372081
Infection. 1993 May-Jun;21(3):164-7
pubmed: 7690010
Epidemiol Infect. 2017 Nov;145(15):3243-3263
pubmed: 28988562
Int J Hepatol. 2022 Dec 29;2022:8109977
pubmed: 36618760
J Nephrol. 2022 Dec;35(9):2269-2282
pubmed: 36383211
Curr Opin Nephrol Hypertens. 2021 Sep 1;30(5):493-500
pubmed: 34054074
Kidney Int. 2019 Apr;95(4):939-947
pubmed: 30904068
Semin Dial. 2019 Mar;32(2):127-134
pubmed: 30569604
Sci Rep. 2022 Jan 10;12(1):330
pubmed: 35013390
BMC Nephrol. 2019 Oct 28;20(1):388
pubmed: 31656166